Delaware | | | 85-1388175 |
(State or other jurisdiction of incorporation or organization) | | | (I.R.S. Employer Identification Number) |
Large accelerated filer | | | ☒ | | | Accelerated filer | | | ☐ |
Non-accelerated filer | | | ☐ | | | Smaller reporting company | | | ☐ |
| | | | Emerging growth company | | | ☐ |
(1) | up to 101,465,310 shares of the Company’s Class A common stock, par value $0.0001 per share (the “Class A common stock”) consisting of (i) 97,631,991 shares of Class A common stock registered for sale by the selling securityholders named in the Registration Statement (the “Selling Securityholders”) (including the shares referred to in the following clause (ii)), (ii) 135,000 shares of Class A common stock issuable upon the exercise of 135,000 warrants held by the Selling Securityholders (the “Private Placement Warrants”), and (iii) 3,833,319 shares of Class A common stock issuable upon the exercise of 3,833,319 warrants included in the units issued by the Company in its initial public offering, each of which is exercisable for one share of Class A common stock, in accordance with its terms (the “Public Warrants”); |
(2) | the resale of up to 19,937,500 shares of the Company’s Class B common stock, par value $0.0001 per share (the “Class B common stock”) held by the Selling Securityholders, which are convertible into 19,937,500 shares of Class A common stock; and |
(3) | the resale of up to 135,000 Private Placement Warrants, which represent warrants to acquire 135,000 shares of Class A common stock. |
(1) | Represents the number of shares of Class A common stock and Class B common stock outstanding as of June 30, 2022. Includes (i) 119,244,128 shares of Class A common stock and (ii) 19,937,500 shares of Class A common stock issuable upon conversion of outstanding Class B common stock. The number of issued and outstanding shares of Class A Common Stock does not include the shares of Class A common stock reserved for issuance under the Quantum-Si Incorporated 2021 Equity Incentive Plan. |
• | the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition and our ability to grow and manage growth profitably and retain our key employees; |
• | the ability to maintain the listing of our Class A common stock on Nasdaq; |
• | changes in applicable laws or regulations; |
• | our ability to raise financing in the future; |
• | the success, cost and timing of our product development activities; |
• | the commercialization and adoption of our existing products and the success of any product we may offer in the future; |
• | the potential attributes and benefits of our products once commercialized; |
• | our ability to obtain and maintain regulatory approval for our products, and any related restrictions and limitations of any approved product; |
• | our ongoing leadership transition; |
• | our ability to identify, in-license or acquire additional technology; |
• | our ability to maintain our existing license agreements and manufacturing arrangements; |
• | our ability to compete with other companies currently marketing or engaged in the development of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than us; |
• | the size and growth potential of the markets for our products, and the ability of each to serve those markets once commercialized, either alone or in partnership with others; |
• | our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |
• | our financial performance; and |
• | the impact of the COVID-19 pandemic on our business. |
| | Shares of Class A Common Stock Beneficially Owned Prior to this Offering** | | | Shares of Class B Common Stock Beneficially Owned Prior to this Offering | | | Private Placement Warrants Beneficially Owned prior to Offering | | | Number of Shares of Class A Common Stock Being Offered | | | Number of Shares of Class B Common Stock Being Offered*** | | | Number of Private Placement Warrants Being Offered | | | Shares of Class A Common Stock Beneficially Owned After the Offered Shares of Class A Common Stock are Sold | | | Shares of Class B Common Stock Beneficially Owned After the Offered Shares of Class A Common Stock are Sold | | | Private Placement Warrants Beneficially Owned After the Offered Warrants are Sold | |||||||||||||||||||
Selling Securityholders | | | Shares | | | Percent | | | Shares | | | Percent | | | Shares | | | Percent | | | Shares | | | Percent | | | Shares | | | Percent | | | Shares | | | Percent | |||||||||
4C Holdings I, LLC(1)(2) | | | 17,943,750 | | | 15.0% | | | 17,943,750 | | | 90% | | | — | | | — | | | 17,943,750 | | | 17,943,750 | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
2012 JMR Trust Common LLC(1) | | | 6,230,108 | | | 5.2% | | | — | | | — | | | — | | | — | | | 6,230,108 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Eldridge PIPE Holdings, LLC(3) | | | 4,483,800 | | | 3.8% | | | — | | | — | | | — | | | — | | | 4,483,800 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
YF Genomics Limited(4) | | | 3,809,713 | | | 3.2% | | | — | | | — | | | — | | | — | | | 3,809,713 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Shanghai Yunfeng Qihui Investment Center (LP)(5) | | | 3,809,713 | | | 3.2% | | | — | | | — | | | — | | | — | | | 3,809,713 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
HighCape Capital Acquisition LLC(6) | | | 2,628,750 | | | 2.2% | | | — | | | — | | | 135,000 | | | 100% | | | 2,628,750 | | | — | | | 135,000 | | | — | | | — | | | — | | | — | | | — | | | — |
Jonathan M. Rothberg, Ph.D.(1)(7) | | | 2,542,882 | | | 2.1% | | | — | | | — | | | — | | | — | | | 2,522,370 | | | — | | | — | | | 20,512 | | | * | | | — | | | — | | | — | | | — |
ARK PIPE Fund I LLC(3) | | | 2,000,000 | | | 1.7% | | | — | | | — | | | — | | | — | | | 2,000,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
4C Holdings V, LLC(1)(2) | | | 1,993,750 | | | 1.7% | | | 1,993,750 | | | 10% | | | — | | | — | | | 1,993,750 | | | 1,993,750 | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Glenview Capital Master Fund, Ltd.(8) | | | 1,824,114 | | | 1.5% | | | — | | | — | | | — | | | — | | | 1,824,114 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
23rd Century Capital LLC(1) | | | 1,917,067 | | | 1.6% | | | — | | | — | | | — | | | — | | | 1,917,067 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Glenview Capital Opportunity Fund, L.P.(8) | | | 1,578,899 | | | 1.3% | | | — | | | — | | | — | | | — | | | 1,578,899 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Deerfield Partners, L.P.(9) | | | 1,400,000 | | | 1.2% | | | — | | | — | | | — | | | — | | | 400,000 | | | — | | | — | | | 1,000,000 | | | * | | | — | | | — | | | — | | | — |
NVR TR, LLC(1) | | | 1,250,000 | | | 1.0% | | | — | | | — | | | — | | | — | | | 1,250,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
JNR TR, LLC(1) | | | 1,250,000 | | | 1.0% | | | — | | | — | | | — | | | — | | | 1,250,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
JAR TR, LLC(1) | | | 1,250,000 | | | 1.0% | | | — | | | — | | | — | | | — | | | 1,250,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
GBR TR, LLC(1) | | | 1,250,000 | | | 1.0% | | | — | | | — | | | — | | | — | | | 1,250,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
EJR TR, LLC(1) | | | 1,250,000 | | | 1.0% | | | — | | | — | | | — | | | — | | | 1,250,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
HighCape Partners QP II, L.P.(10) | | | 1,175,473 | | | 1.0% | | | — | | | — | | | — | | | — | | | 1,175,473 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
CD-Venture GMBH(11) | | | 1,111,413 | | | * | | | — | | | — | | | — | | | — | | | 300,000 | | | — | | | — | | | 811,413 | | | * | | | — | | | — | | | — | | | — |
Foresite Capital Fund V, L.P.(12) | | | 924,379 | | | * | | | — | | | — | | | — | | | — | | | 348,125 | | | — | | | — | | | 576,254 | | | * | | | — | | | — | | | — | | | — |
Michael P. McKenna, Ph.D.(13) | | | 869,021 | | | * | | | — | | | — | | | — | | | — | | | 869,021 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Glenview Offshore Opportunity Fund, L.P.(8) | | | 845,571 | | | * | | | — | | | — | | | — | | | — | | | 845,571 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Hildred Holdings, LLC (Series F)(14) | | | 684,567 | | | * | | | — | | | — | | | — | | | — | | | 684,567 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Jeffrey S. Samberg Amended and Restated Revocable Trust Indenture(15) | | | 650,000 | | | * | | | — | | | — | | | — | | | — | | | 200,000 | | | — | | | — | | | 450,000 | | | * | | | — | | | — | | | — | | | — |
Foresite Capital Opportunity Fund V, L.P.(12) | | | 633,626 | | | * | | | — | | | — | | | — | | | — | | | 633,626 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Glenview Institutional Partners, L.P.(8) | | | 611,356 | | | * | | | — | | | — | | | — | | | — | | | 611,356 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
HighCape Partners II QSI Invest, L.P.(10) | | | 601,000 | | | * | | | — | | | — | | | — | | | — | | | 601,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
TY INVEST KG(16) | | | 532,767 | | | * | | | — | | | — | | | — | | | — | | | 300,000 | | | — | | | — | | | 232,767 | | | * | | | — | | | — | | | — | | | — |
Novalis Lifesciences Investments I, LP(1)(17) | | | 500,000 | | | * | | | — | | | — | | | — | | | — | | | 500,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Michael J. Rothberg Family Trust u/a/d September 4, 1998, as amended, Michael J. Rothberg, Trustee(1) | | | 485,000 | | | * | | | — | | | — | | | — | | | — | | | 485,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Matthew Dyer, Ph.D.(1)(18) | | | 424,677 | | | * | | | — | | | — | | | — | | | — | | | 424,677 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Joseph D. Samberg Revocable Trust(19) | | | 416,557 | | | * | | | — | | | — | | | — | | | — | | | 100,000 | | | — | | | — | | | 316,557 | | | * | | | — | | | — | | | — | | | — |
Michael Mina, Ph.D.(20) | | | 379,387 | | | * | | | — | | | — | | | — | | | — | | | 358,875 | | | — | | | — | | | 20,512 | | | * | | | — | | | — | | | — | | | — |
Acadia Woods Partners, LLC(21) | | | 300,000 | | | * | | | — | | | — | | | — | | | — | | | 300,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Claudia Drayton(1)(22) | | | 287,099 | | | * | | | — | | | — | | | — | | | — | | | 287,099 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Bonnie E. Gould Rothberg, M.D.(1) | | | 273,422 | | | * | | | — | | | — | | | — | | | — | | | 273,422 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Arrivi Vermogensverwaltungs GMBH(23) | | | 252,750 | | | * | | | — | | | — | | | — | | | — | | | 50,000 | | | — | | | — | | | 202,750 | | | * | | | — | | | — | | | — | | | — |
Glenview Capital Partners, L.P.(8) | | | 249,170 | | | * | | | — | | | — | | | — | | | — | | | 249,170 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
John Stark(1) | | | 245,996 | | | * | | | — | | | — | | | — | | | — | | | 245,996 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Christian LaPointe, Ph.D.(1)(24) | | | 207,693 | | | * | | | — | | | — | | | — | | | — | | | 207,693 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
IB Invest GMBH(25) | | | 186,098 | | | * | | | — | | | — | | | — | | | — | | | 50,000 | | | — | | | — | | | 136,098 | | | * | | | — | | | — | | | — | | | — |
Marijin Dekkers, Ph.D.(1)(26) | | | 170,512 | | | * | | | — | | | — | | | — | | | — | | | 150,000 | | | — | | | — | | | 20,512 | | | * | | | — | | | — | | | — | | | — |
Ruth Fattori(1)(27) | | | 170,512 | | | * | | | — | | | — | | | — | | | — | | | 150,000 | | | — | | | — | | | 20,512 | | | * | | | — | | | — | | | — | | | — |
Elizabeth A. Whayland(1) | | | 147,876 | | | * | | | — | | | — | | | — | | | — | | | 147,876 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Glenview Healthcare Master Fund, L.P.(8) | | | 140,890 | | | * | | | — | | | — | | | — | | | — | | | 140,890 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
| | Shares of Class A Common Stock Beneficially Owned Prior to this Offering** | | | Shares of Class B Common Stock Beneficially Owned Prior to this Offering | | | Private Placement Warrants Beneficially Owned prior to Offering | | | Number of Shares of Class A Common Stock Being Offered | | | Number of Shares of Class B Common Stock Being Offered*** | | | Number of Private Placement Warrants Being Offered | | | Shares of Class A Common Stock Beneficially Owned After the Offered Shares of Class A Common Stock are Sold | | | Shares of Class B Common Stock Beneficially Owned After the Offered Shares of Class A Common Stock are Sold | | | Private Placement Warrants Beneficially Owned After the Offered Warrants are Sold | |||||||||||||||||||
Selling Securityholders | | | Shares | | | Percent | | | Shares | | | Percent | | | Shares | | | Percent | | | Shares | | | Percent | | | Shares | | | Percent | | | Shares | | | Percent | |||||||||
EKG Verwaltungs GmbH(28) | | | 147,499 | | | * | | | — | | | — | | | — | | | — | | | 30,000 | | | — | | | — | | | 117,499 | | | * | | | — | | | — | | | — | | | — |
Darius Shahida(1)(29) | | | 142,191 | | | * | | | — | | | — | | | — | | | — | | | 25,000 | | | — | | | — | | | 117,191 | | | * | | | — | | | — | | | — | | | — |
Matt Dyer and Rose Dyer, as Joint Tenants with Right of Survivorship(1) | | | 142,118 | | | * | | | — | | | — | | | — | | | — | | | 142,118 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Albert Boehringer(30) | | | 100,000 | | | * | | | — | | | — | | | — | | | — | | | 100,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Elizabeth A. Whayland and Gregory T. Mulhern, as Joint Tenants With Right of Survivorship(1) | | | 85,790 | | | * | | | — | | | — | | | — | | | — | | | 85,790 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Kevin Rakin(31) | | | 59,512 | | | * | | | — | | | — | | | — | | | — | | | 39,000 | | | — | | | — | | | 20,512 | | | * | | | — | | | — | | | — | | | — |
The Kevin L Rakin Irrevocable Trust(32) | | | 50,000 | | | * | | | — | | | — | | | — | | | — | | | 50,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
David Colpman(33) | | | 30,000 | | | * | | | — | | | — | | | — | | | — | | | 30,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Antony Loebel(33) | | | 30,000 | | | * | | | — | | | — | | | — | | | — | | | 30,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Robert Taub(33) | | | 30,000 | | | * | | | — | | | — | | | — | | | — | | | 30,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Dr. Olaf Gabbert(34) | | | 25,114 | | | * | | | — | | | — | | | — | | | — | | | 6,000 | | | — | | | — | | | 19,114 | | | * | | | — | | | — | | | — | | | — |
Green Cedar GST Trust(35) | | | 25,000 | | | * | | | — | | | — | | | — | | | — | | | 25,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
HighCape Partners II, L.P.(10) | | | 24,527 | | | * | | | — | | | — | | | — | | | — | | | 24,527 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Andrew Rothberg(1) | | | 15,000 | | | * | | | — | | | — | | | — | | | — | | | 15,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Sarah Rakin(1) | | | 2,000 | | | * | | | — | | | — | | | — | | | — | | | 2,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Julia Rakin(1) | | | 2,000 | | | * | | | — | | | — | | | — | | | — | | | 2,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Liam Dagan Rakin(1) | | | 1,000 | | | * | | | — | | | — | | | — | | | — | | | 1,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Gaby Dagan Rakin(1) | | | 1,000 | | | * | | | — | | | — | | | — | | | — | | | 1,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Perry Piep(1) | | | 1,000 | | | * | | | — | | | — | | | — | | | — | | | 1,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Abe Piep(1) | | | 1,000 | | | * | | | — | | | — | | | — | | | — | | | 1,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Nathyn Piep(1) | | | 1,000 | | | * | | | — | | | — | | | — | | | — | | | 1,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Hannah Hoffman(1) | | | 1,000 | | | * | | | — | | | — | | | — | | | — | | | 1,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Ari Hoffman(1) | | | 1,000 | | | * | | | — | | | — | | | — | | | — | | | 1,000 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Total | | | 72,807,109 | | | 51.0% | | | 19,937,500 | | | 100% | | | 135,000 | | | 100% | | | 68,724,906 | | | 19,937,500 | | | 135,000 | | | 4,082,203 | | | 2.93% | | | — | | | — | | | — | | | — |
* | Denotes less than 1%. |
** | Certain Selling Securityholders may be deemed to beneficially own other shares reported herein. |
*** | The Class A common stock issuable upon conversion of shares of Class B common stock is also included in the Number of Shares of Class A Common Stock Being Offered column immediately preceding. |
(1) | Unless otherwise indicated, the business address of each of these holders is c/o Quantum-Si Incorporated, 530 Old Whitfield Street, Guilford, CT 06437. |
(2) | Represents Class B common stock, or Class A common stock issuable upon the conversion of Class B common stock, as the case may be, held by 4C Holdings I, LLC and 4C Holdings V, LLC. Jonathan M. Rothberg, Ph.D., our Interim Chief Executive Officer and Executive Chairman, is the sole manager of 4C Holdings I, LLC and 4C Holdings V, LLC. Dr. Rothberg has sole voting and investment control over the shares. |
(3) | The business address of such holder is 600 Steamboat Road, Suite 200, Greenwich, Connecticut 06830. |
(4) | The business address of such holder is Rooms 1801-02, 18th Floor, China Evergrande Centre, 38 Gloucester Road, Wanchai, Hong Kong. |
(5) | The business address of such holder is 42F, Park Place Office Tower 1601 Nanjing Road(W), Shanghai 200040. |
(6) | HighCape Capital Acquisition LLC, or its affiliates, is the record holder of the 2,088,750 Founder Shares and 405,000 private placement shares that were purchased in connection with HighCape’s initial public offering, reported herein. Also includes 135,000 shares upon the exercise of Private Placement Warrants. Mr. Zuga is the sole manager of HighCape Capital Acquisition LLC, and he has voting and investment discretion with respect to the securities held by HighCape Capital Acquisition LLC. Mr. Zuga disclaims any beneficial ownership of the securities held by HighCape Capital Acquisition LLC other than to the extent of any pecuniary interest he may have therein, directly or indirectly. The business address of HighCape Capital Acquisition LLC is 452 Fifth Avenue, 21st Floor, New York, NY 10018. |
(7) | Represents (i) 1,029,207 shares of Class A common stock held by Dr. Rothberg and (ii) 1,513,675 restricted stock units held by Dr. Rothberg. No shares of Class A common stock are issuable upon vesting of restricted stock units within 60 days of June 30, 2022 held by Dr. Rothberg. |
(8) | Larry Robbins is Founder, Portfolio Manager and CEO of Glenview Capital Management, LLC, which serves as investment manager to Glenview Capital Master Fund, Ltd., Glenview Capital Opportunity Fund, L.P., Glenview Offshore Opportunity Master Fund, Ltd., Glenview Healthcare Master Fund, L.P., Glenview Institutional Partners, L.P., and Glenview Capital Partners, L.P. (the “Glenview Investment Funds”). Mr. Robbins shares voting and dispositive power over the shares held by the Glenview Investment Funds and may be deemed to beneficially own such shares. The address of the principal business office for the Glenview Investment Funds is 767 Fifth Avenue, 44th Floor, New York, New York 10153. |
(9) | Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P. Mr. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P. and Deerfield Management Company, L.P. Each of Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Mr. James E. Flynn may be deemed to beneficially own the shares of Class A common stock of the Company beneficially owned by Deerfield Partners, L.P. The principal business address of Mr. Flynn, Deerfield Mgmt, Deerfield Partners and Deerfield Management is 345 Park Avenue South, New York, New York 10010. |
(10) | Kevin Rakin and Matt Zuga are each a General Partner of HighCape Partners QP II, L.P., HighCape Partners II, L.P., and HighCape Partners II QSI Invest, L.P. and have voting and investment control over the shares held by the entities. The business address of such holders is 452 Fifth Avenue, 21st Floor, New York, New York, 10018. |
(11) | Christoph Boehringer and Dirk Wilken are each a Managing Partner of CD-Venture GMBH and have voting and investment power over the shares held by the entity. The business address of such holder is Bergheimer Str. 45, Heidelberg, Germany BW 69115. |
(12) | Foresite Capital Management V, LLC (“FCM V”) is the general partner of Foresite Capital Fund V, L.P. (“Foresite V”), and Foresite Capital Opportunity Management V, LLC (“FCM Opportunity”) is the general partner of Foresite Capital Opportunity Fund V, L.P. (“Foresite Opportunity”), and may be deemed to have sole voting and dispositive power over shares held by Foresite V and Foresite Opportunity, respectively. Dr. James Tananbaum is the sole managing member of FCM V and FCM Opportunity and may be deemed to have sole voting and dispositive power over shares held by Foresite V and Foresite Opportunity. Each of FCM V, FCM Opportunity, and Dr. Tananbaum disclaims beneficial ownership of shares held by Foresite V and Foresite Opportunity except to the extent of any pecuniary interest therein. The address of Foresite V, Foresite Opportunity, FCM V, FCM Opportunity and Dr. Tananbaum is 900 Larkspur Landing Circle, Suite 150, Larkspur, CA 94939. |
(13) | Represents (i) 814,195 shares of Class A common stock held by Dr. McKenna and (ii) 54,826 restricted stock units held by Dr. McKenna. No shares of Class A common stock are issuable upon vesting of restricted stock units within 60 days of June 30, 2022 held by Dr. McKenna. |
(14) | David Solomon is the Managing Member of Hildred Holdings, LLC (Series F) and has voting and investment power over the shares held by the entity. The business address of such holder is 745 Fifth Avenue, Suite 1702, New York, New York 10151. |
(15) | Jeffrey S. Samberg, is the Trustee of The Jeffrey S. Samberg Amended and Restated Revocable Trust Indenture and has voting and investment power over the shares held by the trust. The business address of such holder is 77 Bedford Road, Katonah, New York 10536. |
(16) | Ferdinand von Baumbach, Andrea von Baumbach, and Peter Zschech have voting and investment power over the shares held by TY INVEST KG. The business address of such holder is Seitzstrasse 8e, Munich, Germany 80538. |
(17) | Dr. Dekkers has sole voting and investment control over the shares held by Novalis Lifesciences Investments I, LP. |
(18) | Represents 424,677 shares of Class A common stock that are issuable upon exercise of options held by Dr. Dyer, which are exercisable within 60 days of June 30, 2022. |
(19) | Joseph D. Samberg, is the Trustee of The Joseph D. Samberg Revocable Trust and has voting and investment power over the shares held by the trust. The business address of such holder is 77 Bedford Road, Katonah, New York 10536. |
(20) | Represents 358,875 shares of Class A common stock that are issuable upon exercise of options held by Dr. Mina, of which 129,593 shares of Class A common stock are exercisable within 60 days of June 30, 2022 held by Dr. Mina. |
(21) | Jeffrey Samberg is the Managing Member of Acadia Woods Partners, LLC and has voting and investment power over the shares held by the entity. The business address of such holder is 77 Bedford Road, Katonah, New York 10536. |
(22) | Represents (i) 23,925 shares of Class A common stock held by Ms. Drayton, (ii) 191,399 shares of Class A common stock that are issuable upon exercise of options held by Ms. Drayton, and (iii) 71,775 restricted stock units held by Ms. Drayton. 47,849 shares of Class A common stock are exercisable within 60 days of June 30, 2022 held by Ms. Drayton and no shares of Class A common stock are issuable upon vesting of restricted stock units within 60 days of June 30, 2022 held by Ms. Drayton. |
(23) | Hubertus von Baumbach has voting and investment power over the shares held by Arrivi Vermogensverwaltungs GMBH. The business address of such holder is Binger Strasse 173, Ingelheim am Rhein, Germany 55216. |
(24) | Represents (i) 90,579 shares of Class A common stock held by Dr. LaPointe and (ii) 138,406 shares of Class A common stock issuable upon the vesting of restricted stock units held by Dr. LaPointe. No shares of Class A common stock are issuable upon the vesting of restricted stock units within 60 days of June 30, 2022 held by Dr. LaPointe. |
(25) | Sebastian Kofler has voting and investment power over the shares held by IB Invest GMBH. The business address of such holder is Binger Str 173, Ingelheim, Germany 55216. |
(26) | Represents 56,837 shares of Class A common stock held by Dr. Dekkers and 113,675 restricted stock units held by Dr. Dekkers. No shares of the Company’s Class A common stock are issuable upon vesting of restricted stock units within 60 days of June 30, 2022 held by Dr. Dekkers. |
(27) | Represents 56,837 shares of Class A common stock held by Ms. Fattori and 113,675 restricted stock units held by Ms. Fattori. No shares of the Company’s Class A common stock are issuable upon vesting of restricted stock units within 60 days of June 30, 2022 held by Ms. Fattori. |
(28) | Erich K. G. von Baumbach has voting and investment power over the shares held by EKG Verwaltungs GmbH. The business address of such holder is Bingerstrasse 173, Ingelheim, Germany 55216. |
(29) | Represents (i) 128,136 shares of Class A common stock held by Mr. Shahida and (ii) 14,055 shares of Class A common stock that that are issuable upon exercise of options held by Mr. Shahida, which are exercisable within 60 days of June 30, 2022. |
(30) | The business address of such holder is Kaethe-Leichter-gasse 7, Vienna, Austria 1130. |
(31) | The business address of such holder is 452 Fifth Avenue, 21st Floor, New York, NY 10018. |
(32) | Mr. Rakin is the Trustee of The Kevin L Rakin Irrevocable Trust and has voting and investment power over the shares held by the trust. The business address of such holder is 452 Fifth Avenue, 21st Floor, New York, NY 10018. |
(33) | The business address of such holder is 452 Fifth Avenue, 21st Floor, New York, NY 10018. |
(34) | The business address of such holder is Butjadingerstrasse 400, Oldenburg, Germany 26125. |
(35) | Shahriar Shahida is the Trustee of the Green Cedar GST Trust and has voting and investment power over the shares held by the trust. The business address of such holder is 3 Heathcote Road, Scarsdale, New York 10583. |
• | banks, financial institutions, or financial services entities; |
• | broker-dealers; |
• | governments or agencies or instrumentalities thereof; |
• | regulated investment companies; |
• | real estate investment trusts; |
• | expatriates, former citizens, or former long-term residents of the United States; |
• | persons that actually or constructively own five percent or more (by vote or value) of our securities (except to the limited extent set forth below); |
• | persons that acquired our securities pursuant to an exercise of employee share options, in connection with employee stock incentive plans or otherwise as compensation; |
• | insurance companies; |
• | dealers or traders subject to a mark-to-market method of accounting with respect to our securities (except to the limited extent set forth below); |
• | persons for whom our securities constitute “qualified small business stock” within the meaning of Section 1202 of the Code or as “Section 1244 stock” for purposes of Section 1244 of the Code; |
• | persons holding our securities shares as part of a “straddle,” constructive sale, hedge, conversion or other integrated or similar transaction; |
• | U.S. Holders (as defined below) whose functional currency is not the U.S. dollar; |
• | Subchapter S corporations, partnerships or entities or arrangements classified as partnerships or other pass-through entities for U.S. federal income tax purposes and any beneficial owners of such partnerships or pass-through entities; |
• | tax-exempt entities; |
• | controlled foreign corporations (including “specified foreign corporations”); and |
• | passive foreign investment companies. |
• | an individual who is a citizen or resident of the United States as determined for United States federal income tax purposes; |
• | a corporation (or other entity taxable as a corporation) organized in or under the laws of the United States, any state thereof or the District of Columbia; |
• | an estate the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or |
• | a trust, if (i) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more United States persons (as defined in the Code) have authority to control all substantial decisions of the trust or (ii) it has a valid election in effect under Treasury Regulations to be treated as a United States person. |
• | a non-resident alien individual (other than certain former citizens and residents of the United States subject to U.S. tax as expatriates); |
• | a foreign corporation; or |
• | an estate or trust that is not a U.S. Holder; but generally does not include an individual who is present in the United States for 183 days or more in the taxable year of the disposition (as such days are calculated pursuant to Section 7701(b) (3) of the Code). If you are such an individual, you should consult your tax advisor regarding the U.S. federal income tax consequences of the acquisition, ownership or sale or other disposition of our securities. |
• | the gain is effectively connected with the conduct by the Non-U.S. Holder of a trade or business within the United States (and, under certain income tax treaties, is attributable to a United States permanent establishment or fixed base maintained by the Non-U.S. Holder); or |
• | we are or have been a “United States real property holding corporation” for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the Non-U.S. Holder held our securities, and, in the case where shares of our Class A common stock are regularly traded on an established securities market, as defined pursuant to |
• | purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus; |
• | ordinary brokerage transactions and transactions in which the broker solicits purchasers; |
• | block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; |
• | an over-the-counter distribution in accordance with the rules of Nasdaq; |
• | through trading plans entered into by a Selling Securityholder pursuant to Rule 10b5-1 under the Exchange Act that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans; |
• | short sales; |
• | distribution to employees, members, limited partners or stockholders of the Selling Securityholders; |
• | through the writing or settlement of options or other hedging transaction, whether through an options exchange or otherwise; |
• | by pledge to secured debts and other obligations; |
• | delayed delivery arrangements; |
• | to or through underwriters or agents; |
• | in “at the market” offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents; |
• | in privately negotiated transactions; |
• | in options transactions; and |
• | through a combination of any of the above methods of sale, as described below, or any other method permitted pursuant to applicable law. |
(1) | Any sale, assignment, transfer, conveyance, hypothecation, or other transfer or disposition, directly or indirectly, of any Class B common stock or any legal or beneficial interest in such share, whether or not for value and whether voluntary or involuntary or by operation of law (including by merger, consolidation, or otherwise), including, without limitation the transfer of a share of Class B common stock to a broker or other nominee or the transfer of, or entering into a binding agreement with respect to, voting control over such share by proxy or otherwise, other than a permitted transfer; |
(2) | Upon the first date on which Jonathan M. Rothberg, Ph.D., together with all other qualified stockholders, collectively cease to beneficially own at least 20% of the number of Class B common stock (as such number of shares is equitably adjusted in respect of any reclassification, stock dividend, subdivision, combination, or recapitalization of the Class B common stock) collectively beneficially owned by Dr. Rothberg and permitted transferees of Class B common stock as of the effective time of the Merger; or |
(3) | Upon the date specified by the affirmative vote of the holders of at least two-thirds (2/3) of the outstanding shares of Class B common stock, voting as a separate class. |
• | in whole and not in part; |
• | at a price of $0.01 per Public Warrant; |
• | upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each Public Warrant holder; and |
• | if, and only if, the closing price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before we send the notice of redemption to the Public Warrant holders. |
• | Registration rights. Promptly, but in any event within 60 days following the closing of the Business Combination, we were required to use our commercially reasonable efforts to file a registration statement under the Securities Act to permit the public resale of all registrable securities as permitted by Rule 415 of the Securities Act and to cause such registration statement to be declared effective as soon as practicable after the filing thereof, but in no event later than 60 days following the filing deadline (or 90 days following the filing deadline if the registration statement is reviewed by and receives comments from the SEC). On July 2, 2021, we filed such registration statement with the SEC and the registration statement was declared effective on July 21, 2021. At any time at which we have an effective shelf registration statement with respect to a holder’s registrable securities, any such holder may request to sell all or a portion of their registrable securities pursuant to an underwritten offering pursuant to such shelf registration statement, provided that such holder(s) reasonably expect any such sales to generate aggregate gross proceeds in excess of $25 million or reasonably expect to sell all of the registrable securities held by such holder, but in no event for aggregate gross proceeds of less than $5 million in gross proceeds. We will enter into an underwriting agreement with a managing underwriter or underwriters selected by the initiating holder(s), after consultation with us, and will take all such other reasonable actions as are requested by the managing underwriter to expedite or facilitate the disposition of such registrable securities. |
• | Demand registration rights. At any time after the closing of the Business Combination, if we do not have an effective registration statement outstanding, we will be required, upon the written request of the holders of at least a majority-in-interest of the then-outstanding registrable securities held by the Sponsor Group Holders or the Quantum-Si Holders, as soon as practicable but not more than 45 days after receipt of such written request, to file a registration statement and to effect the registration of all or part of their registrable securities. We are not obligated to effect more than an aggregate of three registrations pursuant to a demand registration request. |
• | Piggyback registration rights. At any time after the closing of the Business Combination, if we propose to file a registration statement under the Securities Act to register any of our equity securities, or securities or other obligations exchangeable or convertible into equity securities, or to conduct a public offering, either for our own account or for the account of any other person, subject to certain exceptions and reductions as described in the Amended and Restated Registration Rights Agreement, then we will give written notice of such proposed filing to the holders of registrable securities as soon as practicable but not less than 10 days before the anticipated filing of such registration statement. Upon the written request of any holder of registrable securities in response to such written notice, we will, in good faith, cause such registrable securities to be included in the registration statement and use our commercially reasonable efforts to cause the underwriters of any proposed underwritten offering to include such holders’ registrable securities on the same terms and conditions as any similar securities of the Company included in such registration. |
(1) | prior to such time the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; |
(2) | upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation |
(3) | at or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2∕3% of the outstanding voting stock which is not owned by the interested stockholder. |
(1) | Our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on March 1, 2022; |
(2) | The portions of our Definitive Proxy Statement on Schedule 14A for our 2022 Annual Meeting of Stockholders filed with the SEC on March 29, 2022 that are deemed “filed” with the SEC under the Exchange Act; |
(3) | Our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2022 filed with the SEC on May 10, 2022; |
(4) | Our Current Reports on Form 8-K filed with the SEC on January 4, 2022, February 14, 2022, May 9, 2022, May 16, 2022, June 10, 2022 and June 16, 2022 (except for the information furnished under Items 2.02 or 7.01 and the exhibits furnished thereto); |
(5) | The description of our common stock contained in our Registration Statement on Form 8-A filed on September 2, 2020, including any amendment or report filed for the purpose of updating such description; and |
(6) | All reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this prospectus and prior to the termination or completion of the offering of securities under this prospectus shall be deemed to be incorporated by reference in this prospectus and to be a part hereof from the date of filing such reports and other documents. |
Item 14. | Other Expenses of Issuance and Distribution. |
Expense | | | Estimated Amount |
Securities and Exchange Commission registration fee | | | $141,403.81 |
Accounting fees and expenses | | | * |
Legal fees and expenses | | | * |
Financial printing and miscellaneous expenses | | | * |
Total | | | $* |
* | These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be defined at this time. |
Item 15. | Indemnification of Directors and Officers. |
Item 16. | Exhibits. |
Exhibit Number | | | Exhibit Description | | | Filed Herewith | | | Incorporated by Reference herein from Form or Schedule | | | Filing Date | | | SEC File/ Reg. Number |
2.1† | | | | | | | Form 8-K (Exhibit 2.1) | | | 2/18/2021 | | | 001-39486 | ||
4.1 | | | | | | | Form 8-K (Exhibit 3.1) | | | 6/15/2021 | | | 001-39486 | ||
4.2 | | | | | | | Form 10-K (Exhibit 3.2) | | | 3/1/2022 | | | 001-39486 | ||
4.3 | | | | | | | Form S-4/A (Exhibit 4.1) | | | 5/11/2021 | | | 333-253691 | ||
4.4 | | | | | | | Form 8-K (Exhibit 4.1) | | | 9/9/2020 | | | 001-39486 | ||
5.1 | | | | | | | POS AM (Exhibit 5.1) | | | 3/2/2022 | | | 333-257676 | ||
23.1 | | | | | | | X | | | | | ||||
23.2 | | | | | | | | | | | |||||
24.1 | | | | | | | | | | |
† | Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. |
Item 17. | Undertakings. |
(1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
(i) | To include any prospectus required by Section 10(a)(3) of the Securities Act; |
(ii) | To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and |
(iii) | To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; |
(2) | That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
(3) | To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
(4) | That, for the purpose of determining liability under the Securities Act to any purchaser: |
(i) | each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and |
(ii) | Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. |
(5) | That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: |
(i) | Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
(ii) | Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; |
(iii) | The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and |
(iv) | Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
| | QUANTUM-SI INCORPORATED | ||||
| | | | |||
| | By: | | | /s/ Jonathan M. Rothberg, Ph.D. | |
| | | | Jonathan M. Rothberg, Ph.D. Interim Chief Executive Officer |
Signature | | | Title | | | Date |
/s/ Jonathan M. Rothberg, Ph.D. | | | Interim Chief Executive Officer and Executive Chairman (Principal Executive Officer) | | | July 15, 2022 |
Jonathan M. Rothberg, Ph.D. | | |||||
| | | | |||
/s/ Claudia Drayton | | | Chief Financial Officer (Principal Financial and Accounting Officer) | | | July 15, 2022 |
Claudia Drayton | | |||||
| | | | |||
/s/ Vikram Bajaj, Ph.D. | | | Director | | | July 15, 2022 |
Vikram Bajaj, Ph.D. | | |||||
| | | | |||
* | | | Director | | | July 15, 2022 |
Marijn Dekkers, Ph.D. | | |||||
| | | | |||
* | | | Director | | | July 15, 2022 |
Ruth Fattori | | |||||
| | | | |||
* | | | Director | | | July 15, 2022 |
Brigid A. Makes | | |||||
| | | | |||
* | | | Director | | | July 15, 2022 |
Michael Mina, M.D., Ph.D. | |
Signature | | | Title | | | Date |
| | | | |||
* | | | Director | | | July 15, 2022 |
Kevin Rakin | |
By: | | | /s/ Claudia Drayton | | | |
| | Claudia Drayton Attorney-in-fact | |